Relationship of P-Selectin Glycoprotein Ligand-1 to Prognosis in Patients With Multiple Myeloma

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 15; no. 3; pp. 164 - 170
• Main Authors: Atalay, Figen, Ateşoğlu, Elif Birtaş, Yıldız, Semsi, Firatlı-Tuglular, Tülin, Karakuş, Sema, Bayık, Mahmut
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2015
• Subjects: Aged; Bone Marrow - metabolism; Bone Marrow - pathology; CD162; Disease Progression; Female; Hematology, Oncology and Palliative Medicine; Humans; Immunocytochemistry; Immunohistochemistry; Male; Membrane Glycoproteins - genetics; Membrane Glycoproteins - metabolism; Middle Aged; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - genetics; Multiple Myeloma - metabolism; Multiple Myeloma - mortality; Multiple Myeloma - therapy; Neoplasm Grading; Neoplasm Staging; P-selectin ligand protein; Prognosis; Survival Analysis; Treatment Outcome; P-selectin ligand protein; CD162; Prognosis; Immunocytochemistry; Multiple myeloma
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2014.09.005

Micro-Abstract The aim of the present study was to investigate the relationship between PSGL-1 expression in the bone marrow and the known prognostic factors for multiple myeloma disease, disease stage, and survival. D162 staining and the staining degree, with the other standard immunohistochemical stains, were shown to be beneficial in the diagnosis of multiple myeloma disease. However, the results did not provide information about the disease course.